SFM
TVRD

Signet Financial Management’s Tvardi Therapeutics TVRD Stock Holding History

Signet Financial Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$2K – 1396
2021
Q4 		$2K Buy
+4
New +$2.01K ﹤0.01% 1365
2018
Q4 		– Sell
-8
Closed -$7K – 873
2018
Q3 		$7K Hold
8
– – ﹤0.01% 711
2018
Q2 		$6K Buy
+8
New +$4.07K ﹤0.01% 702

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Signet Financial Management's TVRD Position: Q1 2022 in Review

Signet Financial Management sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 4 shares — an estimated $2K sold.

Signet Financial Management first reported a position in TVRD in Q2 2018 and held it in 3 quarters. The position peaked at $7K in Q3 2018. 183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Signet Financial Management reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 4 Tvardi Therapeutics shares in Q1 2022, an estimated $2K.
  • Signet Financial Management first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 3 quarters.
  • Signet Financial Management's Tvardi Therapeutics position peaked at $7K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.